PRLD Stock Forecast: Prelude Therapeutics, Inc. Price Predictions for 2026-2027
The 5 Wall Street analysts covering Prelude Therapeutics, Inc. hold a median 12-month price target of $8 — +147.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 92 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Prelude Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (94): Sales and profits are climbing, and climbing faster than before.
Issuance (35): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PRLD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PRLD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +147.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 18 Nov 2026 | HC Wainwright & Co. | Reiterates | Buy | $8.00 |
| 17 Sept 2026 | JP Morgan | Initiates | Overweight | $12 |
| 29 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $8.00 |
| 15 May 2026 | Goldman Sachs | Initiates | Early-Stage Biotech | — |
| 4 May 2026 | D. Boral Capital | Initiates | Buy | $9.00 |
| 27 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $8.00 |
| 11 Mar 2026 | Citizens | Maintains | Market Outperform | — |
| 23 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Aug 2025 | JMP Securities | Maintains | Market Outperform | — |
| 5 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 Apr 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 8 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Mar 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
| 11 Dec 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 8 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 28 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Sept 2024 | HC Wainwright & Co. | Upgrade | Buy | — |
| 16 Sept 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 16 Sept 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 10 Sept 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PRLD.
This page is one stock. Monday covers all of them.
PRLD appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PRLD vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Prelude Therapeutics, Inc. returned +101.9% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
PRLD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 11.8×
- Price / book
- 2.7×
- EV / EBITDA
- —
Cheaper than 11% of US stocks
Cheaper than 34% of US stocks
- Revenue growth (YoY)
- −13.1%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 14% of US stocks
- Return on equity
- −58.4%
- Return on assets
- −28.0%
- Dividend yield
- —
Higher than 20% of US stocks
Higher than 15% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Prelude Therapeutics, Inc. has a market value of $260.6M and an enterprise value of $213.7M.
Revenue in the twelve months to 30 June 2026: $22.4M.
Net income over the same four quarters: −$60.5M, a −269.7% net margin.
Free cash flow in the twelve months to 30 June 2026: −$33.3M.
Prelude Therapeutics, Inc. employs 79 people — $284K of revenue per employee.
Data provided by Twelve Data
PRLD and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PRLD’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Prelude Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PRLD
What is the PRLD stock price forecast for 2026-2027?
The 5 Wall Street analysts covering Prelude Therapeutics, Inc. have a median 12-month price target of $8, with estimates ranging from $6 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PRLD stock a buy right now?
Of the 5 analysts covering Prelude Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Prelude Therapeutics, Inc. 92 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PRLD?
As at 21 Nov 2026, Prelude Therapeutics, Inc. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (94 of 100).
Will PRLD stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts implies +147.7% from the last close, and Ticker Nerd's factor model ranks Prelude Therapeutics, Inc. 92 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PRLD stock forecast for 2030?
No analyst covering Prelude Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRLD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $12 over the next 12 months.
How has PRLD stock performed over the past year?
Prelude Therapeutics, Inc. returned +101.9% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Prelude Therapeutics, Inc. do?
Prelude Therapeutics Incorporated is a clinical-stage precision oncology company focused on discovering and developing novel medicines for cancer patients with high unmet medical needs. Prelude Therapeutics Incorporated is advancing a pipeline of targeted therapies designed to address genetically defined cancers and other difficult-to-treat tumors.
About Prelude Therapeutics, Inc.
Prelude Therapeutics Incorporated is a clinical-stage precision oncology company focused on discovering and developing novel medicines for cancer patients with high unmet medical needs. Prelude Therapeutics Incorporated is advancing a pipeline of targeted therapies designed to address genetically defined cancers and other difficult-to-treat tumors. Its current programs include small-molecule candidates aimed at key cancer-driving mechanisms such as JAK2V617F, KAT6A, and SMARCA2, as well as approaches for myeloproliferative neoplasms, myelofibrosis, polycythemia vera, essential thrombocythemia, and breast cancer. The company’s work centers on precision medicine, using selective drug design to improve specificity against validated oncology targets. Prelude Therapeutics Incorporated operates as part of the biotechnology sector and plays a role in translating molecular biology insights into potential treatment options for underserved cancer populations.
CEO Dr. Krishna Vaddi D.V.M., Ph.D. · 79 employees · United States · https://preludetx.com